Gemcitabine-based chemogene therapy for pancreatic cancer using Ad-dCK::UMK GDEPT and TS/RR siRNA strategies

Neoplasia

Volumn 11, Issue 7, 2009, Pages 637-650

  Réjiba, Soukaina ^a,b   Bigand, Christelle ^a   Parmentier, Céline ^a   Hajri, Amor ^a  

^a IRCAD   (France)

^b NONE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; CASPASE 3; DEOXYCYTIDINE KINASE; DEOXYCYTIDINE KINASE URIDINE MONOPHOSPHATE KINASE; GEMCITABINE; HYBRID PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; RIBONUCLEOTIDE REDUCTASE; SMALL INTERFERING RNA; THYMIDYLATE SYNTHASE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GENE THERAPY; CANCER INHIBITION; CANCER SURVIVAL; CELL METABOLISM; CELL PROLIFERATION; CHEMOSENSITIVITY; CHEMOSENSITIZATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; DRUG EFFICACY; DRUG EXPOSURE; DRUG POTENTIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FUSION GENE; GENE ACTIVITY; GENE DIRECTED ENZYME PRODRUG THERAPY; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE; TUMOR VOLUME; TUMOR XENOGRAFT; UPREGULATION; WESTERN BLOTTING;

EID: 67650485895     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.81686     Document Type: Article

References (49)

1. Yeo TP, Hruban RH, Leach SD, Wilentz RE, Sohn TA, Kern SE, Iacobuzio-Donahue CA, Maitra A, Goggins M, Canto MI, et al. (2002). Pancreatic cancer. Curr Probl Cancer 26, 176-275.
2. Kollmannsberger C, Peters HD, and Fink U (1998). Chemotherapy in advanced pancreatic adenocarcinoma. Cancer Treat Rev 24, 133-156.
3. Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, et al. (1997). Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreatic cancer: a randomized-trial. J Clin Oncol 15, 2403-2413.
4. Burris H and Storniolo AM (1997). Assessing clinical benefit in the treatment of pancreas cancer: gemcitabine compared to 5-fluorouracil. Eur J Cancer 33 (Suppl), 18-22.
5. Rothenberg ML, Moore MJ, Cripps MC, Andersen JS, Portenoy RK, Burris HA III, Green MR, Tarassoff PG, Brown TD, Casper ES, et al. (1996). A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol 7, 347-353.
6. Abratt RP, Bezwoda WR, Falkson G, Goedhals L, Hacking D, and Rugg TA (1994). Efficacy and safety profile of gemcitabine in non-small cell lung cancer. Phase II study. J Clin Oncol 12, 1535-1540.
7. Lund B, Hansen OP, Theilade K, Hansen M, and Neijit JP (1994). Phase II study of gemcitabine (2′,2′-difluorodeoxycytidine) in previously treated ovarian cancer patients. J Natl Cancer Inst 86, 1530-1533.
8. Heinemann V (2001). Gemcitabine: progress in the treatment of pancreatic cancer. Oncology 60, 8-18.
9. Heinemann V, Schulz L, Issels RD, and Plunkett W (1995). Gemcitabine: a modulator of intracellular nucleotide and deoxynucleotide metabolism. Semin Oncol 22, 11-18.
10. Bouffard DY, Laliberte J, and Momparler RL (1993). Kinetic studies on 2′,2′-difluorodeoxycytidine (gemcitabine) with purified human deoxycytidine kinase and cytidine deaminase. Biochem Pharmacol 45, 1857-1861.
11. Plunkett W, Huang P, Xu YZ, Heinemann V, Grunewald R, and Gandhi V (1995). Gemcitabine: metabolism, mechanism of action, and self-potentiation. Semin Oncol 22 (Suppl), 3-10.
12. Heinemann V, Hertel LW, Grindey GB, and Plunkett W (1988). Comparison of the cellular pharmacokinetics and toxicity of 2,2-difluorodeoxycytidine and 1-β-D-arabinofuranosylcytosine. Cancer Res 48, 4024-4031.
13. Huang P, Chubb S, Hertel LW, Grindey GB, and Plunkett W (1991). Action of 2′,2′-difluorodeoxycytidine on DNA synthesis. Cancer Res 51, 6110-6117.
14. Ruiz van Haperen VW, Veerman G, Vermorken JB, and Peters GJ (1993). 2′,2′-Difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines. Biochem Pharmacol 46, 762-766.
15. Bergman AM, Pinedo HM, and Peters GJ (2002). Determinants of resistance to 2′,2′-difluorocytidine (gemcitabine). Drug Resist Updat 5, 19-33.
16. Beausejour CM, Gagnon J, Primeau M, and Momparler RL (2002). Cytotoxic activity of 2′,2′-difluorodeoxycytidine, 5-aza-2′- deoxycytidine and cytosine arabinoside in cells transduced with deoxycytidine kinase gene. Biochem Biophys Res Commun 293, 1478-1484.
17. Galmarini CM, Clarke ML, Jordheim L, Santos CL, Cros E, Mackey JR, and Dumontet C (2004). Resistance to gemcitabine in a human follicular lymphoma cell line is due to partial deletion of the deoxycytidine kinase gene. BMC Pharmacol 4, 8.
18. Bergman AM, Giaccone G, van Moorsel CJ, Mauritz R, Noordhuis P, Pinedo HM, and Peters GJ (2000). Cross-resistance in the 2′,2′- difluorodeoxycytidine (gemcitabine)-resistant human ovarian cancer cell line AG6000 to standard and investigational drugs. Eur J Cancer 36, 1974-1983.
19. Manome Y, Wen PY, Dong Y, Tanaka T, Mitchell BS, Kufe DW, and Fine HA (1996). Viral vector transduction of the human deoxycytidine kinase cDNA sensitizes glioma cells to the cytotoxic effects of cytosine arabinoside in vitro and in vivo. Nat Med 2, 567-573.
20. Van der Wilt CL, Kroep JR, Bergman AM, Loves WJ, Alvarez E, Talianidis I, Eriksson S, van Groeningen CJ, Pinedo HM, and Peters GJ (2000). The role of deoxycytidine kinase in gemcitabine cytotoxicity. Adv Exp Med Biol 486, 287-290.
21. Van Rompay AR, Johansson M, and Karlsson A (2000). Phosphorylation of nucleosides and nucleoside analogs by mammalian nucleoside monophosphate kinases. Pharmacol Ther 87, 189-198.
22. Galmarini CM, Mackey JR, and Dumontet C (2001). Nucleoside analogues: mechanisms of drug resistance and reversal strategies. Leukemia 15, 875-890.
23. Galmarini CM, Mackey JR, and Dumontet C (2002). Nucleoside analogues and nucleobases in cancer treatment. Lancet Oncol 3, 415-424.
24. Vernejoul F, Laurent Ghénassia L, Souque A, Lulka H, Drocourt D, Cordelier P, Pradayrol L, Pyronnet S, Buscail L, and Tiraby G (2006). Gene therapy based on gemcitabine chemosensitization suppresses pancreatic tumor growth. Mol Ther 14, 758-767.
25. Goan YG, Zhou B, Hu E, Mi S, and Yen Y (1999). Overexpression of ribonucleotide reductase as a mechanism of resistance to 2,2- difluorodeoxycytidine in the human KB cancer cell line. Cancer Res 59, 4204-4207.
26. Eriksson S and Martin DW Jr (1981). Ribonucleotide reductase in cultured mouse lymphoma cells. Cell cycle-dependent variation in the activity of subunit protein M2. J Biol Chem 256, 9436-9440.
27. Duxbury MS, Ito H, Zinner MJ, Ashley SW, and Whang EE (2004). RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine. Oncogene 23, 1539-1548.
28. Graham FL and Prevec L (1991). Manipulation of adenovirus vectors. In Murray EJ (ed.), Methods in Molecular Biology. Gene Transfer and Expression Protocols, vol. 7, Clifton, NJ: The Humana Press, Inc., 109-128.
29. Peng HH, Wu S, Davis JJ, Wang L, Roth JA, Marini FC III, and Fang B (2006). A rapid and efficient method for purification of recombinant adenovirus with RGD-modified fibers. Anal Biochem 354, 140-147.
30. Mackey JR, Mani RS, Selner M, Mowles D, Young JD, Belt JA, Crawford CR, and Cass CE (1998). Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer Res 58, 4349-4357.
31. Arlt A, Vorndamm J, Breitenbroich M, Fölsch UR, Kalthoff H, Schmidt WE, and Schäfer H (2001). Inhibition of NF-kappaB sensitizes human pancreatic carcinoma cells to apoptosis induced by etoposide (VP16) or doxorubicin. Oncogene 20, 859-868.
32. Nakano Y, Tanno S, Koizumi K, Nishikawa T, Nakamura K, Minoguchi M, Izawa T, Mizukami Y, Okumura T, and Kohgo Y (2007). Gemcitabine chemo-resistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells. Br J Cancer 96, 457-463.
33. Duxbury MS, Ito H, Zinner MJ, Ashley SW, and Whang EE (2004). Inhibition of SRC tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cells. Clin Cancer Res 10, 2205-2207.
34. Giroux V, Malicet C, Barthet M, Gironella M, Archange C, Dagorn JC, Vasseur S, and Iovanna JL (2006). p8 is a new target of gemcitabine in pancreatic cancer cells. Clin Cancer Res 12, 235-241.
35. Bergman AM, Eijk PP, Ruiz van Haperen VW, Smid K, Veerman G, Hubeek I, van den Ijssel P, Ylstra B, and Peters GJ (2005). In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as the major determinant. Cancer Res 65, 9510-9516.
36. Van der wilt CL, Pinedo HM, Smid K, and Peters GJ (1992). Elevation of thymidylate synthase following 5-fluorouracil treatment is prevented by the addition of leucovorin in murine colon tumors. Cancer Res 52, 4922-4928.
37. Csapo Z, Sasvari-Szekely M, Spasokoukotskaja T, Talianidis I, Eriksson S, and Staub M (2001). Activation of deoxycytidine kinase by inhibition of DNA synthesis in human lymphocytes. Biochem Pharmacol 61, 191-197.
38. Shrikhande SV, Kleeff J, Kayed H, Keleg S, Reiser C, Giese T, Büchler MW, Esposito I, and Friess H (2006). Silencing of X-linked inhibitor of apoptosis (XIAP) decreases gemcitabine resistance of pancreatic cancer cells. Anticancer Res 26, 3265-3273.
39. Denlinger CE, Rundall BK, Keller MD, and Jones DR (2004). Proteasome inhibition sensitizes non-small-cell lung cancer to gemcitabine-induced apoptosis. Ann Thorac Surg 78, 1207-1214.
40. Pace E, Melis M, Siena L, Bucchieri F, Vignola AM, Profita M, Gjomarkaj M, and Bonsignore G (2000). Effects of gemcitabine on cell proliferation and apoptosis in non small cell lung cancer (NSCLC) cell lines. Cancer Chemother Pharmacol 46, 467-476.
41. Ferreira CG, Tolis C, Span SW, Peters GJ, van Lopik T, Kummer AJ, Pinedo HM, and Giaccone G (2000). Drug-induced apoptosis in lung cancer cells is not mediated by the Fas/FasL (CD95/APO1) signaling pathway. Clin Cancer Res 6, 203-212.
42. Wack S, Rejiba S, Parmentier C, Aprahamian M, and Hajri A (2008). Telomerase transcriptional targeting of inducible Bax/TRAIL gene therapy improves gemcitabine treatment of pancreatic cancer. Mol Ther 16, 252-260.
43. Lin T, Zhang L, Davis J, Gu J, Nishizaki M, Ji L, Roth JA, Xiong M, and Fang B (2003). Combination of TRAIL gene therapy and chemotherapy enhances antitumor and antimetastasis effects in chemosensitive and chemoresistant breast cancers. Mol Ther 8, 441-448.
44. Arlt A and Schäfer H (2002). NFkappaB-dependent chemoresistance in solid tumors. Int J Clin Pharm Ther 40, 336-347.
45. Wang W, Abbruzzese JL, Evans DB, and Chiao PJ (1999). Overexpression of urokinase-type plasminogen activator in pancreatic adenocarcinoma is regulated by constitutively activated RelA. Oncogene 18, 4554-4563.
46. Dong QG, Sclabas GM, Fujioka S, Schmidt C, Peng B, Wu T, Tsao MS, Evans DB, Abbruzzese JL, McDonnell TJ, et al. (2002). The function of multiple IkappaB : NF-kappaB complexes in the resistance of cancer cells to Taxol-induced apoptosis. Oncogene 21, 6510-6519.
47. Mattson MP, Goodman Y, Luo H, Fu W, and Furukawa K (1997). Activation of NF-kappaB protects hippocampal neurons against oxidative stress-induced apoptosis: evidence for induction of manganese superoxide dismutase and suppression of peroxynitrite production and protein tyrosine nitration. J Neurosci Res 49, 681-697.
48. Krysko DV, Leybaert L, Vandenabeele P, and D'Herde K (2005). Gap junctions and the propagation of cell survival and cell death signals. Apoptosis 10, 459-469.
49. Pratesi G, Petrangolini G, Tortoreto M, Addis A, Belluco S, Rossini A, Selleri S, Rumio C,Menard S, and Balsari A (2005). Therapeutic synergism of gemcitabine and CpG-oligodeoxynucleotides in an orthotopic human pancreatic carcinoma xenograft. Cancer Res 65, 6388-6393.